Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12094-015-1429-1 http://scihub22266oqcxt.onion/10.1007/s12094-015-1429-1 C4689754!4689754!26497354     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Transl+Oncol 2015 ; 17 (ä): 1005-13 Nephropedia Template TP {{tp|p=26497354|t=2015. SEOM clinical guidelines for the treatment of Hodgkin?s lymphoma |pdf=|usr=}}{{26497354}} gab.com Text SEOM clinical guidelines for the treatment of Hodgkin s lymphoma JO: Clin Transl Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26497354 #FOAvip Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10?15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Twit Text FOAVip SEOM clinical guidelines for the treatment of Hodgkin s lymphoma ????Clin Transl Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26497354 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26497354 #FOAvip English Wikipedia <ref>{{Cite pmid|26497354}}</ref> SEOM clinical guidelines for the treatment of Hodgkin?s lymphoma #MMPMID26497354 Rueda Domínguez A; Alfaro Lizaso J; de la Cruz Merino L; Gumá i Padró J; Quero Blanco C; Gómez Codina J; Llanos Muñoz M; Martinez Banaclocha N; Rodriguez Abreu D; Provencio Pulla M Clin Transl Oncol 2015[]; 17 (ä): 1005-13 PMID26497354show ga Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10?15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. äSEOM clinical guidelines for the treatment of Hodgkin?s lymphoma (epmc).pdf DeepDyve Pubget Overpricing